english.prescrire.org > Prescrire International > N°123 - January 2012

n°123

January 2012

Issue Contents
Editorial

Free  Daring to take action, daring to be unpopular

p.4
France's regional pharmacovigilance centres can do much to protect patients' health

New Products


Cabazitaxel (New Drug)

p.5-7
Uncertain efficacy, high toxicity

Dasatinib in first-line treatment of chronic myeloid leukaemia (New Indication)

p.7
Choose imatinib, a better-known drug

Free  Fentanyl nasal (New Drug)

p.8
Still no tangible advantage of intranasal administration

Sumatriptan without a prescription (Regulatory Status)

p.9
Application rejected in France

Golimumab for recent-onset highly active rheumatoid arthritis (New Indication)

p.10
Continue to use a better-known TNF-alpha antagonist

Adverse Effects


Drug-induced weight gain

p.11-14
Mostly psychotropics and sex hormones

Meprobamate + aceprometazine combination withdrawn in France at last

p.14
Long overdue

Citalopram: torsades de pointes

p.15
Hypokalaemia and bradycardia are risk factors

Montelukast: psychiatric disorders

p.15
Confirmation of known adverse effects

Weekly methotrexate: still more deaths in France in 2011

p.15
Preventable

Varenicline: long-term cardiovascular events

p.15
Consistent data

Reviews


Sedation at end of life

p.16-20
When distress is unbearable despite treatment

Preoperative skin antisepsis

p.20
Clinical advantage with chlorhexidine

Outlook


Free  Attitudes must change if we are to avoid another Mediator° scandal

p.21-23
Analysis and proposals

Free  European Medicines Agency: complete transparency needed

p.23-24
Trial protocols and raw data

Queries and comments. Hay fever: why use the sublingual route for desensitisation?

p.24-26

Free  Prescrire International turns 20

p.28

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe